Short-contact therapy with tazarotene in psoriasis vulgaris [5]

Dermatology

Volumn 206, Issue 4, 2003, Pages 347-348

  Veraldi, Stefano ^a   Schianchi, Rossana ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Psoriasis; Short contact therapy; Tazarotene

Indexed keywords

CORTICOSTEROID; TAZAROTENE;

ADULT; AGED; BURN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EDEMA; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; IRRITANT DERMATITIS; LETTER; MALE; MEDICAL EXAMINATION; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; SHORT COURSE THERAPY; XEROSIS;

ADMINISTRATION, TOPICAL; ADULT; AGED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC ACIDS; PSORIASIS; TREATMENT OUTCOME;

EID: 0038316369     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069953     Document Type: Letter

References (3)

1. Chandraratna RA: Tazarotene: The first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997;37:S12-S17.
2. Gollnick HP, Finzi AF, Marks R, Barker JN, Jansen C, Revuz J, Saurat J: Optimising the use of tazarotene in clinical practice: Consensus statement from the European advisory panel for tazarotene (Zorac™). Dermatology 1999;199:40-46.
3. Bershad S: Short-contact topical receptor-selective retinoid therapy for acne vulgaris. Skin Allergy News 1999;30:12-14.